Published Date: 15-02-2017
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, North America DNA Diagnostics Market, published by KBV Research, the North America DNA Diagnostics Market is expected to grow at a CAGR of 11.4% during 2016 -2022.
The U.S market dominated the North American DNA Diagnostics Market in 2015, and is estimated to grow at a CAGR of 10.6% during the forecast period. The Canada market is expected to attain a market size of $1.3 billion by 2022.
The Instruments market contributed the larger revenue share to the North American DNA Diagnostics Market in 2015, and is expected to grow at a CAGR of 11.9% during the forecast period. The Clinical confirmation diagnostics market dominated the North America DNA Diagnostics Market in 2015. The Infectious disease testing market is expected to grow at CAGR of 11.4% during 2016-2022.
The report highlights the adoption of DNA Diagnostics in North America.Based on the Product Types, the North America DNA Diagnostics Market is segmented into Instruments, Reagents and Service & software segment. Based on the Application, the market is bifurcated into Oncology, Infectious disease testing, Myogenic disorder diagnosis, Clinical confirmation diagnostics, Prenatal diagnosis, Pre-implantation diagnostics andother segments. Based on the Technology, the market is bifurcated into PCR, Microarrays, In situ hybridization, Sequencing Technology, Mass Spectrometry andother segments. Further, the market is segmented into POC (Point-of-Care), Central Laboratories and Self-Testing segments based on the End Users. The countries included in the report are U.S, Canada, Mexico and Rest of North America.
Key Players profiled in the report includes Sysmex Corporation, Bayer Corporation, Roche Diagnostics, Abbott Laboratories, Cepheid Inc, Hologic Corporation, Illumina, Novartis International Ag, Thermo Fisher Scientific Inc. and Bio-Rad Laboratories.
The market is segmented based on Product Types, Application, Technology, End User and Country.